101 related articles for article (PubMed ID: 7615046)
1. Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison.
Björkholm M; Liliemark J; Gahrton G; Grimfors G; Gruber A; Hast R; Juliusson G; Järnmark M; Killander A; Kimby E
Eur J Haematol; 1995 Jul; 55(1):19-23. PubMed ID: 7615046
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
3. DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML).
Gahrton G; Tidefelt U; Paul C; Björkholm M; Grimfors G; Hast R; Juliusson G; Järnmark M; Killander A; Kimby E
Leukemia; 1992; 6 Suppl 2():89-91. PubMed ID: 1578953
[No Abstract] [Full Text] [Related]
4. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Fujiwara M; Satou N; Izumi N; Shibasaki Y; Higashimura M; Tsukada N; Koike T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1793-8. PubMed ID: 18030012
[TBL] [Abstract][Full Text] [Related]
5. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Rees JK; Gray RG
Haematol Blood Transfus; 1990; 33():243-8. PubMed ID: 1691131
[No Abstract] [Full Text] [Related]
6. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
[TBL] [Abstract][Full Text] [Related]
7. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Nørgaard JM; Olesen LH; Olesen G; Meyer K; Kristensen JS; Bendix K; Pedersen B; Kjeldsen E; Hokland P
Eur J Haematol; 2001 Oct; 67(4):221-9. PubMed ID: 11860442
[TBL] [Abstract][Full Text] [Related]
8. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
9. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F
J Clin Oncol; 1991 Jul; 9(7):1210-4. PubMed ID: 2045861
[TBL] [Abstract][Full Text] [Related]
11. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
12. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.
Ruutu T; Koivunen E; Nousiainen T; Pelliniemi TT; Almqvist A; Anttila P; Jantunen E; Koistinen P; Koponen A; Mikkola M; Oksanen K; Pulli T; Remes K; Sarkkinen R; Silvennoinen R; Timonen T; Vanhatalo S; Elonen E;
Eur J Haematol; 2004 Jan; 72(1):38-44. PubMed ID: 14962261
[TBL] [Abstract][Full Text] [Related]
13. [Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Nagata K; Abe Y; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
Gan To Kagaku Ryoho; 1994 Feb; 21(2):231-6. PubMed ID: 8311494
[TBL] [Abstract][Full Text] [Related]
14. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
Schaich M; Illmer T; Aulitzky W; Bodenstein H; Clemens M; Neubauer A; Repp R; Schäkel U; Soucek S; Wandt H; Ehninger G;
Haematologica; 2002 Aug; 87(8):808-15. PubMed ID: 12161356
[TBL] [Abstract][Full Text] [Related]
15. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.
Resegotti L
Leukemia; 1992; 6 Suppl 2():72-5. PubMed ID: 1578948
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone and high dose Ara-C for the treatment of ANLL in childhood: a pilot study of the EORTC CLCG (EORTC 58 872).
Béhar C; Bertrand Y; Rubie H; Vilmer E; Babin A; Brock P; Boutard P; Solbu G; Suciu S; Robert A
Leukemia; 1992; 6 Suppl 2():63-5. PubMed ID: 1578944
[TBL] [Abstract][Full Text] [Related]
18. Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors.
Weinstein H; Grier H; Gelber R; Camitta B; Link M; Delorey M; Price K
Haematol Blood Transfus; 1987; 30():88-92. PubMed ID: 3476388
[No Abstract] [Full Text] [Related]
19. High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study.
Parikh P; Powles R; Treleaven J; Helenglass G; Gore M; Rose M; Talbot D; Milan S; Smith C; Pinkerton R
Br J Cancer; 1990 Nov; 62(5):830-3. PubMed ID: 2245176
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of 2 chemotherapy protocols in adult acute myeloblastic leukemia. Results of the Instituto Nacional de la Nutrición Salvador Zubirán cooperative group].
Lobato-Mendizábal E; Ruiz-Argüelles GJ; Labardini-Méndez J; Gómez-Almaguer D; Ganci-Cerrud G; Lozano-de-la-Vega A
Rev Invest Clin; 1992; 44(1):63-9. PubMed ID: 1523351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
